Riskpilot← Back to searchSign inGet full accessOnkologia AB
ABActiveOrg 5568362494Walleriusvägen 14General medical practice activities · NACE 8621Est. 20101 employees
Revenue 2025
SEK 1,2M
-19% vs 2024
EBITDA margin
80.0%
-24% vs 2024
Equity ratio
99.0%
Financial strength
Net profit 2025
SEK 771K
-24% vs 2024
| Revenue | SEK 1,2M | -19% |
| EBITDA | SEK 957K | -24% |
| Net profit | SEK 771K | -24% |
| Total assets | SEK 5,2M | +10% |
| Equity | SEK 5,1M | +12% |
| Employees | 1 | — |
Legal name
Onkologia AB
Org number
5568362494
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
29 december 2010
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolagets verksamhet ska vara redaktionell verksamhet inom tidskriftsbranschen, föreläsningar inom medicin, läkartjänster samt idka därmed förenlig verksamhet.
Address
Walleriusvägen 14
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 167 | 1 217 | 1 441 | 1 477 | 1 197 |
| Staff expenses | — | −75 | −109 | −140 | −114 |
| EBITDA | 985 | 1 110 | 1 224 | 1 260 | 957 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 985 | 1 110 | 1 224 | 1 260 | 957 |
| Net financials | — | — | 66 | 14 | 13 |
| Profit before tax | 985 | 1 110 | 1 290 | 1 274 | 970 |
| Tax | −211 | −251 | −265 | −262 | −199 |
| Net profit | 774 | 860 | 1 025 | 1 012 | 771 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 349 | 3 190 | 3 899 | 4 692 | 5 171 |
| Equity | 2 227 | 3 087 | 3 735 | 4 552 | 5 118 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 122 | 104 | 164 | 140 | 53 |
| Total debt | 122 | 104 | 164 | 140 | 53 |
EBITDA margin
80.0%
This company
15.8%
Market median
+406% vs market
20212025
Equity ratio
99.0%
This company
38.2%
Market median
+159% vs market
20212025
Return on equity
15.1%
This company
18.4%
Market median
+18% vs market
20212025
Net profit margin
64.4%
This company
8.1%
Market median
+695% vs market
20212025
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Onkologia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Calin Ioan Radu | Deputy Board Member | 0 companies |
| Nina Catharina E Cavalli-Björkman | Board of Directors | 0 companies |